Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of
human tumors are not known. Here we show here that a single infusion of the VEGF-specific …
human tumors are not known. Here we show here that a single infusion of the VEGF-specific …
[HTML][HTML] Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
…, DM Liebovitz, JM Nicklas, K Cohen… - … England Journal of …, 2022 - Mass Medical Soc
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Phase II study of cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
…, T Benner, DN Louis, KS Cohen… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Glioblastoma is an incurable solid tumor characterized by increased expression of
vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in …
vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in …
[PDF][PDF] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
…, E di Tomaso, WT Zhang, DG Duda, KS Cohen… - Cancer cell, 2007 - cell.com
Using MRI techniques, we show here that normalization of tumor vessels in recurrent
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
glioblastoma patients by daily administration of AZD2171—an oral tyrosine kinase inhibitor of …
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
…, RS Call, R Canadas, LB Chaykin, K Cohen… - The Lancet, 2017 - thelancet.com
Background Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In …
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo
…, JP Zimmer, DG Duda, TS Levchenko, KS Cohen… - Nature medicine, 2005 - nature.com
A solid tumor is an organ composed of cancer and host cells embedded in an extracellular
matrix and nourished by blood vessels. A prerequisite to understanding tumor …
matrix and nourished by blood vessels. A prerequisite to understanding tumor …
[BOOK][B] The way of qigong: The art and science of Chinese energy healing
KS Cohen - 1999 - books.google.com
… "Ken Cohen is a rare combination of expert practitioner, gifted scholar, and lucid writer. He
… For those interested in optimal health, Ken Cohen's book allows you an opportunity not only …
… For those interested in optimal health, Ken Cohen's book allows you an opportunity not only …
[HTML][HTML] Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor
SN Chi, MA Zimmerman, X Yao, KJ Cohen… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose Atypical teratoid rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm
primarily affecting young children, with a historic median survival ranging from 6 to 11 …
primarily affecting young children, with a historic median survival ranging from 6 to 11 …
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group
KJ Cohen, IF Pollack, T Zhou, A Buxton… - Neuro …, 2011 - academic.oup.com
To determine whether temozolomide is an active agent in the treatment of children with high-grade
astrocytomas and whether survival is influenced by the expression of the O6-…
astrocytomas and whether survival is influenced by the expression of the O6-…
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels
Tissue engineering requires formation of a de novo stable vascular network. Because of
their ability to proliferate, differentiate into endothelial cells, and form new vessels, blood-…
their ability to proliferate, differentiate into endothelial cells, and form new vessels, blood-…